Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
NCT05203939Phase 2Active, not recruiting
- Sponsor
- Ocugen
- Start
- Jan 2022
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 2, open-label trial of OCU400 in retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) (8 arms), sponsored by Ocugen. Primary endpoints: Study Drug-related adverse events at 1 year, Treatment-Emergent adverse events at 1 year and 1 more. Started Jan 2022; status: active, not recruiting.
02
Drugs
OCU400
03
Conditions
retinitis pigmentosa (RP)Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on NCT05203939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05203939.